Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexis B Cortot

Showing results (21-30 of 75) with videos related to

Pageof 8
Sort By:
Molecular Oncology|August 5, 2015
PEA3 transcription factors are downstream effectors of Met signaling involved in migration and invasiveness of Met-addicted tumor cellsZoulika Kherrouche, Didier Monte, Elisabeth Werkmeister, et al.
Clinical Lung Cancer|October 9, 2022
Brief Report: First-line Pembrolizumab in Metastatic Non-Small Cell Lung Cancer Habouring MET Exon 14 Skipping Mutation and PD-L1 ≥50% (GFPC 01-20 Study)Florian Guisier, Renaud Descourt, Helene Babey, et al.
Targeted Oncology|November 3, 2023
Histo-Molecular Factors of Response to Combined Chemotherapy and Immunotherapy in Non-Small Cell Lung CancersMarine Marchal, Vincent Leroy, Hélène Behal, et al.
Oncotarget|January 7, 2017
MET receptor variant R970C favors calpain-dependent generation of a fragment promoting epithelial cell scatteringRémi Montagne, Anne Baranzelli, Ghaffar Muharram, et al.
International Journal of Cancer|August 15, 2009
EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancyAntoine Italiano, Alexis B Cortot, Marius Ilie, et al.
Lung Cancer (Amsterdam, Netherlands)|November 16, 2018
MET amplification increases the metastatic spread of EGFR-mutated NSCLCSimon Baldacci, Zoulika Kherrouche, Vincent Cockenpot, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2020
Complete and prolonged response to anti-PD1 therapy in an ALK rearranged lung adenocarcinomaSimon Baldacci, Valérie Grégoire, Enrico Patrucco, et al.
Bulletin Du Cancer|January 22, 2017
[Cancer screening in France: 10 years of analysis of behaviours by the EDIFICE surveys]François Eisinger, Xavier Pivot, Laurent Greillier, et al.
Bulletin Du Cancer|October 10, 2014
[ALK-rearranged non-small cell lung cancer: how to optimize treatment with crizotinib in routine practice?]Clarisse Audigier-Valette, Nicolas Girard, Alexis B Cortot, et al.
Expert Review of Anticancer Therapy|November 22, 2014
ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?Nicolas Girard, Clarisse Audigier-Valette, Alexis B Cortot, et al.
Pageof 8

Showing results (21-30 of 75) with videos related to

Sort By:
Pageof 8
Molecular Oncology|August 5, 2015
PEA3 transcription factors are downstream effectors of Met signaling involved in migration and invasiveness of Met-addicted tumor cellsZoulika Kherrouche, Didier Monte, Elisabeth Werkmeister, et al.
Clinical Lung Cancer|October 9, 2022
Brief Report: First-line Pembrolizumab in Metastatic Non-Small Cell Lung Cancer Habouring MET Exon 14 Skipping Mutation and PD-L1 ≥50% (GFPC 01-20 Study)Florian Guisier, Renaud Descourt, Helene Babey, et al.
Targeted Oncology|November 3, 2023
Histo-Molecular Factors of Response to Combined Chemotherapy and Immunotherapy in Non-Small Cell Lung CancersMarine Marchal, Vincent Leroy, Hélène Behal, et al.
Oncotarget|January 7, 2017
MET receptor variant R970C favors calpain-dependent generation of a fragment promoting epithelial cell scatteringRémi Montagne, Anne Baranzelli, Ghaffar Muharram, et al.
International Journal of Cancer|August 15, 2009
EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancyAntoine Italiano, Alexis B Cortot, Marius Ilie, et al.
Lung Cancer (Amsterdam, Netherlands)|November 16, 2018
MET amplification increases the metastatic spread of EGFR-mutated NSCLCSimon Baldacci, Zoulika Kherrouche, Vincent Cockenpot, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2020
Complete and prolonged response to anti-PD1 therapy in an ALK rearranged lung adenocarcinomaSimon Baldacci, Valérie Grégoire, Enrico Patrucco, et al.
Bulletin Du Cancer|January 22, 2017
[Cancer screening in France: 10 years of analysis of behaviours by the EDIFICE surveys]François Eisinger, Xavier Pivot, Laurent Greillier, et al.
Bulletin Du Cancer|October 10, 2014
[ALK-rearranged non-small cell lung cancer: how to optimize treatment with crizotinib in routine practice?]Clarisse Audigier-Valette, Nicolas Girard, Alexis B Cortot, et al.
Expert Review of Anticancer Therapy|November 22, 2014
ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?Nicolas Girard, Clarisse Audigier-Valette, Alexis B Cortot, et al.
Pageof 8